

PCT

WORLD INTELLECTUAL PROPERTY  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER



(51) International Patent Classification<sup>6</sup> :

A61K 31/505, C07D 405/04

A1

(11) In

WO 9607413A1

(43) International Publication Date: 14 March 1996 (14.03.96)

(21) International Application Number: PCT/US95/11464

(22) International Filing Date: 5 September 1995 (05.09.95)

(30) Priority Data:  
08/301,298 6 September 1994 (06.09.94) US  
08/390,633 17 February 1995 (17.02.95) US

(60) Parent Applications or Grants

(63) Related by Continuation  
US 08/301,298 (CIP)  
Filed on 6 September 1994 (06.09.94)  
US 08/390,633 (CIP)  
Filed on 17 February 1995 (17.02.95)

(71) Applicants (for all designated States except US): UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. [US/US]; Boyd Graduate Studies Research Center, Athens, GA 30602-7411 (US). YALE UNIVERSITY [US/US]; 451 College Street, New Haven, CT 06520 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CHU, Chung, K. [US/US]; 120 Orchard Knob Lane, Athens, GA 30605 (US). CHENG,

Yung-Chi [US/US]; 961 Baldwin Road, Woodbridge, CT 06525 (US).

(74) Agents: ZALESKY, Cheryl, K. et al.; Kilpatrick & Cody, Suite 2800, 1100 Peachtree Street, Atlanta, GA 30309-4530 (US).

(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).

Published

*With international search report.*

*Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER

(57) Abstract

(-)-(2S,4S)-1-(2-Hydroxymethyl-1,3-dioxolan-4-yl)cytosine (also referred to as L-OddC) or its derivative and its use to treat tumors, including cancer, or other abnormal or undesired proliferation of cells, in animals, including humans.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Larvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER

### FIELD OF THE INVENTION

This invention is in the area of medicinal chemistry, and in particular is (-)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine (also referred to as (-)-OddC) or its derivative, and its use to treat cancer in animals, including humans.

### BACKGROUND OF THE INVENTION

A tumor is an unregulated, disorganized proliferation of cell growth. A tumor is malignant, or cancerous, if it has the properties of invasiveness and metastasis. Invasiveness refers to the tendency of a tumor to enter surrounding tissue, breaking through the basal laminas that define the boundaries of the tissues, thereby often entering the body's circulatory system. Metastasis refers to the tendency of a tumor to migrate to other areas of the body and establish areas of proliferation away from the site of initial appearance.

Cancer is now the second leading cause of death in the United States. Over 8,000,000 persons in the United States have been diagnosed with cancer, with 1,208,000 new diagnoses expected in 1994. Over 500,000 people die annually from the disease in this country.

Cancer is not fully understood on the molecular level. It is known that exposure of a cell to a carcinogen such as certain viruses, certain chemicals, or radiation, leads to DNA alteration that inactivates a "suppressive" gene or activates an "oncogene". Suppressive genes are growth regulatory genes, which upon mutation, can no longer control cell growth. Oncogenes are

initially normal genes (called protooncogenes) that by mutation or altered context of expression become transforming genes. The products of transforming genes cause inappropriate cell growth. More than  
5 twenty different normal cellular genes can become oncogenes by genetic alteration. Transformed cells differ from normal cells in many ways, including cell morphology, cell-to-cell interactions, membrane content, cytoskeletal structure, protein  
10 secretion, gene expression and mortality (transformed cells can grow indefinitely).

All of the various cell types of the body can be transformed into benign or malignant tumor cells. The most frequent tumor site is lung,  
15 followed by colorectal, breast, prostate, bladder, pancreas, and then ovary. Other prevalent types of cancer include leukemia, central nervous system cancers, including brain cancer, melanoma, lymphoma, erythroleukemia, uterine cancer, and head  
20 and neck cancer.

Cancer is now primarily treated with one or a combination of three types of therapies: surgery, radiation, and chemotherapy. Surgery involves the bulk removal of diseased tissue. While surgery is  
25 sometimes effective in removing tumors located at certain sites, for example, in the breast, colon, and skin, it cannot be used in the treatment of tumors located in other areas, such as the backbone, nor in the treatment of disseminated  
30 neoplastic conditions such as leukemia.

Chemotherapy involves the disruption of cell replication or cell metabolism. It is used most often in the treatment of leukemia, as well as breast, lung, and testicular cancer.

35 There are five major classes of chemotherapeutic agents currently in use for the treatment of cancer: natural products and their

derivatives; anthracyclines; alkylating agents; antiproliferatives (also called antimetabolites); and hormonal agents. Chemotherapeutic agents are often referred to as antineoplastic agents.

5       The alkylating agents are believed to act by alkylating and cross-linking guanine and possibly other bases in DNA, arresting cell division. Typical alkylating agents include nitrogen mustards, ethyleneimine compounds, alkyl sulfates, 10       cisplatin, and various nitrosoureas. A disadvantage with these compounds is that they not only attack malignant cells, but also other cells which are naturally dividing, such as those of bone marrow, skin, gastro-intestinal mucosa, and fetal 15       tissue.

Antimetabolites are typically reversible or irreversible enzyme inhibitors, or compounds that otherwise interfere with the replication, translation or transcription of nucleic acids.

20       Several synthetic nucleosides have been identified that exhibit anticancer activity. A well known nucleoside derivative with strong anticancer activity is 5-fluorouracil. 5-Fluorouracil has been used clinically in the 25       treatment of malignant tumors, including, for example, carcinomas, sarcomas, skin cancer, cancer of the digestive organs, and breast cancer. 5-Fluorouracil, however, causes serious adverse reactions such as nausea, alopecia, diarrhea, 30       stomatitis, leukocytic thrombocytopenia, anorexia, pigmentation, and edema. Derivatives of 5-fluorouracil with anti-cancer activity have been described in U.S. Patent No. 4,336,381, and in Japanese patent publication Nos. 50-50383, 50- 35       50384, 50-64281, 51-146482, and 53-84981.

U.S. Patent No. 4,000,137 discloses that the peroxidate oxidation product of inosine, adenosine,

or cytidine with methanol or ethanol has activity against lymphocytic leukemia.

Cytosine arabinoside (also referred to as Cytarabin, araC, and Cytosar) is a nucleoside analog of deoxycytidine that was first synthesized in 1950 and introduced into clinical medicine in 1963. It is currently an important drug in the treatment of acute myeloid leukemia. It is also active against acute lymphocytic leukemia, and to a lesser extent, is useful in chronic myelocytic leukemia and non-Hodgkin's lymphoma. The primary action of araC is inhibition of nuclear DNA synthesis. Handschumacher, R. and Cheng, Y., "Purine and Pyrimidine Antimetabolites", Cancer Medicine, Chapter XV-1, 3rd Edition, Edited by J. Holland, et al., Lea and Febigol, publishers.

5-Azacytidine is a cytidine analog that is primarily used in the treatment of acute myelocytic leukemia and myelodysplastic syndrome.

2-Fluoroadenosine-5'-phosphate (Fludara, also referred to as FaraA) is one of the most active agents in the treatment of chronic lymphocytic leukemia. The compound acts by inhibiting DNA synthesis. Treatment of cells with F-araA is associated with the accumulation of cells at the G1/S phase boundary and in S phase; thus, it is a cell cycle S phase-specific drug. Incorporation of the active metabolite, F-araATP, retards DNA chain elongation. F-araA is also a potent inhibitor of ribonucleotide reductase, the key enzyme responsible for the formation of dATP.

2-Chlorodeoxyadenosine is useful in the treatment of low grade B-cell neoplasms such as chronic lymphocytic leukemia, non-Hodgkins' lymphoma, and hairy-cell leukemia. The spectrum of activity is similar to that of Fludara. The

compound inhibits DNA synthesis in growing cells and inhibits DNA repair in resting cells.

Although a number of chemotherapeutic agents have been identified and are currently used for the treatment of cancer, new agents are sought that are efficacious and which exhibit low toxicity toward healthy cells.

Therefore, it is an object of the present invention to provide compounds that exhibit anti-tumor, and in particular, anti-cancer, activity.

It is another object of the present invention to provide pharmaceutical compositions for the treatment of cancer.

It is further object of the present invention to provide a method for the treatment of cancer.

#### SUMMARY OF THE INVENTION


A method and composition for the treatment of tumors, and in particular, cancer, in humans and other host animals is disclosed that includes administering an effective amount of (-)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine (also referred to as (-)-OddC, L-OddC, or (-)-L-OddC), a pharmaceutically acceptable derivative thereof, including a 5' or N<sup>4</sup> alkylated or acylated derivative, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.

In an alternative embodiment, the compounds disclosed herein can be used to treat conditions, specifically those other than tumors or cancer, that involve the abnormal or undesired proliferation of cells. Examples include skin disorders such as hyperkeratosis (including ichthyosis, keratoderma, lichen, planus, and psoriasis), warts, including genital warts, and

blisters, as well as any abnormal or undesired cellular proliferation that can be treated with methotrexate. The active compounds disclosed herein can also be used to induce or facilitate  
5 abortion.

In a preferred embodiment, (-)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine is provided as the indicated enantiomer (the L-enantiomer) and substantially in the absence of its  
10 corresponding enantiomer (i.e., in enantiomerically enriched, including enantiomerically pure form).

It is believed that (-)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine is the first example of an "L"-nucleoside that exhibits  
15 anti-tumor activity. (-)-(2S,4S)-1-(2-Hydroxymethyl-1,3-dioxolan-4-yl)cytosine has the structure illustrated in Formula I.




It has been discovered that (-)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine exhibits  
20 significant activity against cancer cells and exhibits low toxicity toward healthy cells in the host. Nonlimiting examples of cancers that can be treated with this compound include lung, colorectal, breast, prostate, bladder,  
25 nasopharyngeal, pancreas, ovarian, leukemia, lymphoma, head and neck cancer, central nervous system cancer (including brain cancer), cervical carcinoma, melanoma, and hepatocellular cancer.

In an alternative embodiment, a method and  
30 composition for the treatment of tumors, and in particular, cancer, or other abnormal or undesired



proliferation of cells, in humans and other host animals is disclosed that includes administering an effective amount of a derivative of L-OddC of the formula:



- 5 wherein R is F, Cl, -CH<sub>3</sub>, -C(H)=CH<sub>2</sub>, -Br, -NO<sub>2</sub>,  
-C≡CH, or -C≡N and R' is hydrogen, alkyl, acyl,  
monophosphate, diphosphate, or triphosphate, or a  
pharmaceutically acceptable derivative thereof,  
10 optionally in a pharmaceutically acceptable  
carrier, preferably in enantiomerically enriched  
form.

Although the preferred embodiment of this  
invention is the use of the active compounds or  
their derivatives or their salts in the  
15 nonnaturally occurring configuration (the L-  
configuration), the compounds disclosed herein or  
their derivatives or salts can alternatively be  
administered in the naturally occurring  
configuration (the D-configuration) or as a racemic  
20 mixture.

Any of the compounds disclosed herein for use  
in treating tumors can be administered in  
combination or alternation with other anti-tumor  
pharmaceutical agents, to increase the efficacy of  
25 therapy. Examples include natural products and  
their derivatives; anthracyclines; alkylating  
agents; antiproliferatives (also called  
antimetabolites); and hormonal agents.  
Specifically, agents include but are not limited  
30 to, nitrogen mustards, ethyleneimine compounds,  
alkyl sulfates, cisplatin, nitrosoureas, 5-

fluorouracil, cytosine arabinoside, 5-azacytidine, 2-fluoroadenosine-5'-phosphate, 2-chlorodeoxyadenosine, tamoxifen, actinomycin, amsacrine, bleomycin, carboplatin, carmustine, 5 cyclophosphamide, cyclosporin, daunorubicin, doxorubicin, interleukin, lomustine, mercaptopurine, methotrexate, mitomycin, thioguanine, vinblastine, growth factors, including GCSF, GMCSF, and platelet growth factors; 10 adriamycin, WP-16, hydroxyurea, etoposide;  $\alpha$ ,  $\beta$ , and  $\gamma$  interferons, and vincristine. Methods for the administration of effective amounts of these agents are easily determined, or are described, for example, in The Physician's Desk Reference, latest 15 edition, published by Medical Economics Data Production Company, and Martindale, The Extra Pharmacopoeia, latest edition, published by The Pharmaceutical Press. These methods can be modified routinely to optimize the efficacy of 20 combination and alternation therapy.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 indicates the  $ID_{50}$  of (-)-OddC and a combination of (-)-OddC + THU (tetrahydrouridine, a cytidine deaminase inhibitor) on colon cancer 25 cells. The graph plots growth inhibition as a percentage of control growth vs. concentration ( $\mu M$ ). In the graph, the data for (-)-OddC alone is represented by (●) and the data for (-)-OddC + THU is represented by (--▲--).

30 Figure 2 is a graph of tumor growth weight for mouse carcinoma (Colon 38) treated twice a day with (-)-OddC in a dosage amount of 25 mg/kgbid. The graph plots tumor growth as a percentage of original tumor weight vs. days. Treatment of the 35 mice occurred in days 1, 2, 3, 4 and 5. In the

graph, the data for the control (no administration of (-)-OddC) is represented by (●), the data for (-)-OddC is represented by (--▲--).

Figure 3 indicates the survival rate of P388 leukemic mice that have been treated with (-)-OddC. The graph plots percentage of survival vs. days treated. Treatment of the mice occurred in days 1, 2, 3, 4 and 5. In the graph, the survival rate of the control (no administration of (-)-OddC) is represented by (●), the survival rate of those administered (-)-OddC at 25 mg/kgbid twice a day is represented by (--▲--), and the survival rate of mice administered (-)-OddC once a day at 50 mg/kgbid is represented by (○).

Figure 4 is a plot of the relative sensitivity of certain cancer cell lines to (-)-OddC on the basis of GI50. Bars extending to the right represent sensitivity of the cell line to (-)-OddC in excess of the average sensitivity of all tested cell lines. Since the bar scale is logarithmic, a bar 2 units to the right implies the compound achieved GI50 for the cell line at a concentration one-hundredth the mean concentration required over all cell lines, and thus the cell line is unusually sensitive to (-)-OddC. Bars extending to the left correspondingly imply sensitivity less than the mean.

Figure 5 is a graph of the inhibition of human tumor growth by (●)-OddC. Three to six week old NCr nude mice were inoculated subcutaneously in each flank with  $2 \times 10^6$  HepG2 or DU-145 cells. Treatment was started when the tumors were in an advanced stage of growth. Drugs were administered twice a day on days 0 through 4 and tumor sizes were measured on the indicated days. Curves A and B show the drug effects on HepG2 tumors and Du-145 tumors respectively (-○-Control; -●- AraC 25mg/kg, i.p.;

-□-(-)-OddC, 25 mg/kg, p.o.; -■-(-)-OddC, 25 mg/kg, i.p.)). Each data point represents the means ± SD of 10 tumors in graph A and six tumors in graph B.

5

**DETAILED DESCRIPTION OF THE INVENTION**

The invention as disclosed herein is a method and composition for the treatment of tumors, and in particular, cancer, in humans or other host animals, that includes administering an effective amount of (-)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine, a derivative of the compound as defined further herein, including a 5-substituted or 5' or N<sup>4</sup> alkylated or acylated derivative, or a physiologically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.

(-)-(2S,4S)-1-(2-Hydroxymethyl-1,3-dioxolan-4-yl)cytosine is referred to as an "L"-nucleoside. Since the 2 and 5 carbons of the dioxolane ring are chiral, their nonhydrogen substituents (CH<sub>2</sub>OH and the cytosine base, respectively) can be either cis (on the same side) or trans (on opposite sides) with respect to the dioxolane ring system. The four optical isomers therefore are represented by the following configurations (when orienting the dioxolane moiety in a horizontal plane such the oxygen in the 3-position is in front): cis (with both groups "up", which corresponds to the configuration of naturally occurring nucleosides, referred to as a "D"-nucleoside), cis (with both groups "down", which is the non-naturally occurring configuration, referred to as an "L"-nucleoside), trans (with the C2 substituent "up" and the C5 substituent "down"), and trans (with the C2 substituent "down" and the C5 substituent "up"). It is believed that (-)-(2S,4S)-1-(2-hydroxymethyl-


1,3-dioxolan-4-yl)cytosine or its derivative is the first example of an "L"-nucleoside that exhibits anti-tumor activity. This is surprising, in light of the fact that this "L" nucleoside configuration does not occur in nature.

As used herein, the term "enantiomerically enriched" refers to a nucleoside composition that includes at least approximately 95%, and preferably approximately 97%, 98%, 99%, or 100% of a single enantiomer of that nucleoside. In a preferred embodiment, (-)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine or its derivative or salt is provided in a nucleoside composition that consists essentially of one enantiomer, i.e., as the indicated enantiomer (the L-enantiomer) and substantially in the absence of its corresponding D-enantiomer (i.e., in enantiomerically enriched, including enantiomerically pure form).

The active compound can be administered as any derivative that upon administration to the recipient, is capable of providing directly or indirectly, the parent (-)-L-OddC compound or a 5-substituted derivative as defined otherwise herein, or that exhibits activity itself. Nonlimiting examples are the pharmaceutically acceptable salts (alternatively referred to as "physiologically acceptable salts") of (-)-OddC, the 5-derivatives as illustrated above, and the 5' and N<sup>4</sup> acylated or alkylated derivatives of the active compound (alternatively referred to as "physiologically active derivatives"). In one embodiment, the acyl group is a carboxylic acid ester (-C(O)R) in which the non-carbonyl moiety of the ester group is selected from straight, branched, or cyclic alkyl (typically C<sub>1</sub> to C<sub>18</sub>, and more typically C<sub>1</sub> to C<sub>5</sub>), alkaryl, aralkyl, alkoxyalkyl including methoxymethyl, aralkyl including benzyl,

alkyl or C<sub>1</sub> to C<sub>4</sub> alkoxy; sulfonate esters such as  
alkyl or aralkyl sulphonyl including  
methanesulfonyl, the mono, di or triphosphate  
ester, trityl or monomethoxytrityl, substituted  
5 benzyl, trialkylsilyl (e.g. dimethyl-t-butylsilyl)  
or diphenylmethylsilyl. Aryl groups in the esters  
optimally comprise a phenyl group.

Specific examples of pharmaceutically  
acceptable derivatives of L-O-ddC include, but are  
10 not limited to:



wherein R is F, Cl, -CH<sub>3</sub>, -C(H)=CH<sub>2</sub>, -C=CH, or -C≡N,  
-Br, -NO<sub>2</sub>, and R<sub>1</sub> and R<sub>2</sub> are independently selected  
from the group consisting of hydrogen, alkyl and  
acyl, specifically including but not limited to  
15 methyl, ethyl, propyl, butyl, pentyl, hexyl,  
isopropyl, isobutyl, sec-butyl, t-butyl, isopentyl,  
amyl, t-pentyl, 3-methylbutyryl, hydrogen  
succinate, 3-chlorobenzoate, cyclopentyl,  
cyclohexyl, benzoyl, acetyl, pivaloyl, mesylate,  
20 propionyl, butyryl, valeryl, caproic, caprylic,  
capric, lauric, myristic, palmitic, stearic,  
oleic, and amino acids including but not  
limited to alanyl, valinyl, leucinyl, isoleucinyl,  
prolinyl, phenylalaninyl, tryptophanyl,  
25 methioninyl, glyciny, serinyl, threoninyl,  
cysteinyl, tyrosinyl, asparaginyl, glutaminyl,  
aspartoyl, glutaoyl, lysinyl, argininyl, and  
histidinyl. In a preferred embodiment, the  
derivative is provided as the L-

enantiomer and substantially in the absence of its corresponding enantiomer (i.e., in enantiomerically enriched, including enantiomerically pure form).

L-OddC or its derivative can be provided in the form of pharmaceutically acceptable salts. As used herein, the term pharmaceutically acceptable salts or complexes refers to salts or complexes of L-OddC or its derivatives that retain the desired biological activity of the parent compound and exhibit minimal, if any, undesired toxicological effects. Nonlimiting examples of such salts are (a) acid addition salts formed with inorganic acids (for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acids, naphthalenedisulfonic acids, and polygalacturonic acid; (b) base addition salts formed with polyvalent metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, cadmium, sodium, potassium, and the like, or with an organic cation formed from N,N-dibenzylethylene-diamine, ammonium, or ethylenediamine; or (c) combinations of (a) and (b); e.g., a zinc tannate salt or the like.

Modifications of the active compound, specifically at the N<sup>4</sup> and 5'-O positions, can affect the solubility, bioavailability and rate of metabolism of the active species, thus providing control over the delivery of the active species. Further, the modifications can affect the anticancer activity of the compound, in some cases increasing the activity over the parent compound. This can easily be assessed by preparing the


derivative and testing its anticancer activity according to the methods described herein, or other method known to those skilled in the art.

In summary, the present invention  
5 includes the following features:

- (a) (-)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine and derivatives and salts thereof;
- 10 (b) (+)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine and derivatives and salts thereof;
- (c) (-/+)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine and derivatives and salts thereof;
- 15 (d) (-)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine and derivatives and salts thereof, or the (+)-enantiomer or racemic mixture thereof, and pharmaceutically acceptable derivatives  
20 and salts thereof for use in medical therapy, for example for the treatment or prophylaxis of a tumor, including a cancerous tumor;
- 25 (e) use of (-)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine and pharmaceutically acceptable derivatives and salts thereof, or the (+)-enantiomer or racemic mixture thereof, and  
30 pharmaceutically acceptable derivatives and salts thereof in the manufacture of a medicament for treatment of a tumor, including a cancerous tumor;




- (f) pharmaceutical formulations comprising  
 (-)-(2S,4S)-1-(2-hydroxymethyl-1,3-  
 dioxolan-4-yl)cytosine and  
 pharmaceutically acceptable derivatives  
 and salts thereof, or the (+)-enantiomer  
 or racemic mixture thereof, or a  
 pharmaceutically acceptable derivative or  
 salt thereof together with a  
 pharmaceutically acceptable carrier;
- (g) a process for the preparation of (2S,4S)-  
 1-(2-hydroxymethyl-1,3-dioxolan-4-  
 yl)cytosine which comprises:
- (i) reacting optionally protected  
 cytosine with a 1,3-dioxolane of  
 formula A



A

wherein  $R_{1a}$  is hydrogen or a hydroxyl  
 protecting group, including an acyl  
 group, and L is a leaving group; and  
 optionally removing any hydroxyl  
 protecting group.


- (ii) reacting a compound of formula B



B

(wherein  $R_{11}$  is as defined above) with an agent serving to convert the oxo group in the 4-position of the uracil ring to an amino group; any remaining protecting groups being removed to produce the desired product.

- h) a process for the preparation of a (-) or (+) enantiomer of (2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine which comprises subjecting the compound or derivative (e.g. 5'-ester) thereof in the form of a mixture of (-) and (+) enantiomers to conditions or reacting with reagents (for example an appropriate enzyme) serving to separate the enantiomers and if necessary converting the resulting derivative to the parent compound. Alternatively, the mixture can be passed through a chiral liquid chromatography column that separates enantiomers of this type.
- i) a process for the preparation of (2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine which comprises reacting a protected 1,3-dioxolane of the formula:




with a protected cytosine base that is optionally substituted in the 5-position, using a Lewis acid that does

not racemize the product, such as trimethylsilyl triflate.

With regard to process g) (i), the hydroxy protecting group includes protecting groups described in detail below, including acyl (e.g. acetyl), arylacyl (e.g. benzoyl or substituted benzoyl), trityl or monomethoxytrityl, benzyl or substituted benzyl, trisubstituted silyl, including trialkylsilyl (e.g. dimethyl-t-butylsilyl) or diphenylmethysilyl. The cytosine compound can be optionally protected with trisubstituted silyl groups. The protecting groups can be removed in a conventional manner. The leaving group L is a leaving group typical of those known in the art of nucleoside chemistry, e.g. halogen such as chlorine, fluorine, tosyl, mesyl, triflate, or bromine, alkoxy such as methoxy or ethoxy, or acyl such as acetyl or benzoyl.

The reaction in process g) (i) can be carried out in an organic solvent (e.g., 1,2-dichloroethane or acetonitrile) in the presence of a Lewis acid, such as  $\text{SnCl}_4$ , titanium chloride, or trimethylsilyl triflate.

Compounds of formula A (wherein L represents an acyl group, e.g., an acetyl group) can be obtained by reaction of a compound of formula C




C

(wherein  $\text{R}_{12}$  is defined above) with a reducing agent, e.g., lithium aluminum hydride, followed by treatment with the appropriate conventional reagent

for the desired intermediate, for example, a carboxylic acid anhydride, e.g. acetic anhydride, for acylation, chlorinating or brominating reagents for halogenation, or alkylating reagents.

- 5           The compound of formula C can be prepared by reaction of a compound of formula D



E

with HOCH<sub>2</sub>CO<sub>2</sub>H at an elevated temperature.

- 10           The compound of formula E can be prepared by ozonolysis of an allyl ether or ester having the formula CH<sub>2</sub>=CH-CH<sub>2</sub>-OR or a diether or diester of 2-butene-1,3-diol having the formula ROCH<sub>2</sub>-CH=CH-CH<sub>2</sub>OR, in which R is a protecting group, such as an alkyl, silyl, or acyl group.

- 15           With regard to process g) ii), the compound of formula C can be treated with 1,2,4-triazole, together with 4-chlorophenyl dichlorophosphate, to form the corresponding 4-(1,2,4-triazoyl) compound which is then converted to the desired 4-  
20   amino (cytidine) compound by reaction with for example methanol.

- The starting materials of formulas B and C can be prepared for example by reaction of an appropriate (optionally protected) base with a  
25   compound of formula A in an analogous manner to that described in process g) i). Uracil and cytosine are commercially available from Aldrich Chemical Co., Milwaukee, WI 53233, USA.

- 30           L-OddC or its derivative can be converted into a pharmaceutically acceptable ester by reaction with an appropriate esterifying agent, for example, an acid halide or anhydride. L-OddC or its


pharmaceutically acceptable derivative can be converted into a pharmaceutically acceptable salt thereof in a conventional manner, for example, by treatment with an appropriate base. The ester or  
5 salt can be converted into the parent, for example, by hydrolysis.

In an alternative embodiment, the compounds disclosed herein can be used to treat conditions, specifically those other than tumors or cancer,  
10 that involve the abnormal or undesired proliferation of cells. Examples include skin disorders such as hyperkeratosis (including ichthyosis, keratoderma, lichen planus, and psoriasis), warts, including genital warts, and  
15 blisters, as well as any abnormal cellular proliferation that can be treated with methotrexate. The active compounds disclosed herein can also be used to induce or facilitate abortion.

20 Thus, the invention also includes (-)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine and derivatives and salts thereof, or the (+)-enantiomer or racemic mixture thereof, and pharmaceutically acceptable derivatives and salts  
25 thereof for use in medical therapy, for example for the treatment or prophylaxis of an abnormal or undesired proliferation of cells; as well as the use of (-)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine and pharmaceutically acceptable  
30 derivatives and salts thereof, or the (+)-enantiomer or racemic mixture thereof, and pharmaceutically acceptable derivatives and salts thereof in the manufacture of a medicament for the treatment of abnormal or undesired proliferation of  
35 cells.

## II. Preparation of the Active Compounds

(-)-L-OddC and its derivatives can be prepared as described above, according to the method disclosed in detail in PCT International Publication No. WO 92/18517, published on October 29, 1992, by the method disclosed in Scheme 1 and working examples 1-7 provided below, or by any other method known to those skilled in the art. These methods, or other known methods, can be adapted for the preparation of the exemplified derivatives of L-OddC.



Scheme 1: Synthesis of (-)-OddC

**Example 1 Preparation of 6-Anhydro-L-gulose**

6-Anhydro-L-gulose was prepared in one step from L-gulose by the treatment of L-gulose with an acid, e.g., 0.5N HCl, in 60% yield (Evans, M.E., et al., Carbohydr. Res. (1973), 28, 359). Without selective protection, as was done before (Jeong, L. S. et al. Tetrahedron Lett. (1992), 33, 595 and Beach, J. W. et al. J. Org. Chem. (1992, in press), (2) was directly converted to dioxolane triol (3) by oxidation with NaIO<sub>4</sub>, followed by reduction with NaBH<sub>4</sub>, which without isolation, was converted to isopropylidene derivative (4). Benzoylation to (5), deprotection to (6), and oxidation of diol (6) gave the acid (7). Oxidative decarboxylation of (7) with Pb(OAc)<sub>4</sub> in dry THF gave the acetate (8), the key intermediate in good yield. The acetate was condensed with the desired pyrimidines (e.g., silylated thymine and N-acetylcytosine) in the presence of TMSOTf to afford an  $\alpha,\beta$ -mixture, which was separated on a silica gel column to obtain the individual isomers (9 and 10). Debenzoylation with methanolic ammonia gave the desired (-)-OddC (11).

**Example 2: Preparation of (-)-1,6-Anhydro- $\alpha$ -L-gulopyranose (2)**

A mixture of L-gulose (1) (33 g, 0.127 mol) and 0.5 N HCl (330 mL, 0.165 mol) was refluxed for 20 hours. The mixture was cooled and neutralized to pH 6 by a resin (Dowex-2, HCO<sub>3</sub>-form) with air bubbling. The resin was recycled by washing with 10% HCl, water, methanol, water and saturated NaHCO<sub>3</sub> solution. The reaction mixture was filtered and the resin was washed with water (500 mL). The combined filtrate was concentrated to dryness and dried in vacuo overnight. The residue was purified over a column (5 cm depth, silica gel, mesh, CHCl<sub>3</sub>-CH<sub>3</sub>OH, 10:1) to give a slightly yellow solid, which was recrystallized from absolute alcohol to give a colorless solid (2) [ $R_f$  = 0.43 (CHCl<sub>3</sub>-CH<sub>3</sub>OH, 5:1),

7.3g, 35.52%]. The L-gulose  $R_f=0.07$ , 11 g) obtained was recycled to give (2) (5 g, total yield 60%): mp 142.5–145°C;  $^1\text{H}$  NMR (DMSO- $d_6$ )  $\delta$  3.22–3.68 (m, 4H, H-2, -3, -4 and -6a), 3.83 (d,  $J_{6a,6b}=7.25$  Hz, 1H, H<sub>b</sub>-6),  
5 4.22 (pseudo t,  $J_{3,6a}=4.61$  and 4.18 Hz, H, H-5),  
4.46 (d,  $J_{2-OH,2}=6.59$  Hz, 1H, 2-OH, exchangeable with D<sub>2</sub>O), 4.62 (d,  $J_{3-OH,3}=5.28$  Hz, 1H, 3-OH, exchangeable with D<sub>2</sub>O), 5.07 (d,  $J_{4-OH,4}=4.84$  Hz, 1H, 4-OH, exchangeable with D<sub>2</sub>O), 5.20 (d,  $J_{1,2}=2.19$  Hz, 1H, H-1).  $[\alpha]_D^{25}-50.011$  (c, 1.61, CH<sub>3</sub>OH).  
10

**Example 3: Preparation of (-)-(1'S,2S,4S)-4-(1,2-Dihydroxyethyl-1,2-O-Isopropylidene)-2-hydroxymethyl)-dioxolane (4)**

15 A solution of NaIO<sub>4</sub> (22.36 g, 0.1 mol) in water (300 mL) was added in a dropwise manner over 10 minutes to a solution of (2) (11.3 g, 0.07 mol) in methanol (350 mL) cooled to 0°C. The mixture was stirred mechanically for 15 minutes. NaBH<sub>4</sub> (7.91 g,  
20 0.21 mol) was added to this mixture and the reaction mixture was stirred for 10 minutes at 0°C. The white solid was filtered off and the solid was washed with methanol (300 mL). The combined filtrate was neutralized by 0.5 N HCl (~200 mL) and  
25 concentrated to dryness. The residue was dried in vacuo overnight. The syrupy residue was triturated with methanol-acetone (1:5, 1200 mL) using a mechanical stirrer (5 hours) and the white solid (1st.) was filtered off. The filtrate was  
30 concentrated to dryness and the residue was dissolved in acetone (500 mL) and followed by p-toluene sulfonic acid (6.63 g, 0.035 mol). After stirring for 6 hours, the mixture was neutralized by triethylamine, the solid (2nd.) was filtered off  
35 and the filtrate was concentrated to dryness. The residue was dissolved in ethyl acetate (350 mL) and washed with water (50 mL x 2), dried (MgSO<sub>4</sub>), filtered, and evaporated to give crude (4) (3.6 g) as a yellowish syrup. The water layer was



concentrated to dryness and dried in vacuo. The solid obtained (1st and 2nd) was combined with the dried water layer and recycled by stirring for 1 hour in 10% methanol-acetone (900 mL) and p-toluene sulfonic acid (16 g, 0.084 mol) to yield crude (4) (5.6 g). The crude (4) was purified by a dry column over silica gel (CH<sub>3</sub>OH-CHCl<sub>3</sub>, 1%-5%) to give (4) [ $R_f$  = 0.82(CHCl<sub>3</sub>-CH<sub>3</sub>OH, 10:1), 8.8 g, 61.84%] as a colorless oil. <sup>1</sup>H NMR(DMSO-d<sub>6</sub>)  $\delta$  1.26 and 1.32 (2 X s, 2 X 3 H, isopropylidene), 3.41 (dd,  $J_{CH_2OH,OH}$  = 6.04 Hz,  $J_{CH_2OH,2}$  = 3.96 Hz, 2H, CH<sub>2</sub>OH), 3.56-4.16 (m, 6H, H-4, -5, -1' and -2'), 4.82 (t,  $J_{OH,CH_2}$  = 6.0 Hz, 1 H, CH<sub>2</sub>OH, exchangeable with D<sub>2</sub>O), 4.85 (t,  $J_{2OH,CH_2OH}$  = 3.96 Hz, 1H, H-2).  $[\alpha]_D^{25}$  -12.48 (c, 1.11, CHCl<sub>3</sub>). Anal, Calcd for C<sub>9</sub>H<sub>16</sub>O<sub>5</sub>: C, 52.93; H, 7.90. Found: C, 52.95; H, 7.86.

**Example 4: Preparation of (+)-(1'S,2S,4S)-4-(1,2-Dihydroxymethyl-1,2-O-Isopropylidene)-2-(O-benzoyloxymethyl)-dioxolane (5)**

Benzoyl chloride (6.5 mL, 0.056 mol) was added in a dropwise manner to a solution of (4) (8.5 g, 0.042 mol) in pyridine-CH<sub>2</sub>Cl<sub>2</sub> (1:2, 120 mL) at 0°C and the temperature was raised to room temperature. After stirring for 2 hours, the reaction was quenched with methanol (10 mL) and the mixture was concentrated to dryness in vacuo. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (300 mL) and washed with water (100 mL X 2), brine, dried (MgSO<sub>4</sub>), filtered, evaporated to give a yellowish syrup, which was purified by silica gel column chromatography (EtOAc-Hexane 4% -30%) to yield (5) [ $R_f$  = 0.45 (Hexane-EtOAc, 3:1), 10.7 g, 83.4%] as a colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  1.35 and 1.44 (2 X s, 2 X 3H, isopropylidene) 3.3-4.35 (m 6H, H-4, -5, -1' and -2'), 4.44 (d,  $J$ =3.96 Hz, 2H, CH<sub>2</sub>-OBz), 5.29 (t,  $J$ =3.74 Hz, 1H, H-2), 7.3-7.64, 8.02-8.18 (m, 3H, 2H, -OBz).  $[\alpha]_D^{25}$  +10.73 (c, 1.75, CH<sub>3</sub>OH). Anal. Calcd

for  $C_{16}H_{20}O_6$ : C, 62.33; H, 6.54. Found: C, 62.39; H, 6.54.

**Example 5: Preparation of (+)-(1'S,2S,4S)-4-(1,2-Dihydroxyethyl)-2-(O-benzoyloxymethyl)-dioxolane (6)**

5 A mixture of (5) (5.7 g, 0.018 mol) and p-toluene sulfonic acid (1.05 g, 0.0055 mol) in methanol (70 mL) was stirred at room temperature for 2 hours. The reaction was not completed, so  
10 the solvent was evaporated to half of the original volume and additional methanol (50 mL) and p-toluene sulfonic acid (0.7 g, 3.68 mmol) were added. After stirring for one more hour, the reaction mixture was neutralized with triethyl  
15 amine and the solvent was evaporated to dryness.

The residue was purified by silica gel column chromatography (Hexane-EtOAc, 10%-33%) to give (6) [ $R_f=0.15$  (Hexane-EtOAc, 1:1), 4.92 g, 99.2%] as a colorless syrup  $^1H$  NMR (DMSO- $d_6$ )  $\delta$  3.43 (m, 2H, H-2'), 3.67-4.1 (m, 4H, H-4, -5 and -1'), 4.32 (d,  $J=3.73$  Hz, 2H,  $CH_2$ -OBz), 4.60 (t,  $J=5.72$  Hz, 2'-OH, exchangeable with  $D_2O$ ), 5.23 (t,  $J=3.96$  Hz, 1H, H-2), 7.45-7.7, 7.93-8.04 (m, 3H, 2H, -OBz),  $[\alpha]_D^{25} + 9.16$  (c, 1.01,  $CHCl_3$ ). Anal. Calcd for  
25  $C_{13}H_{16}O_6$ : C, 58.20; H, 6.01. Found: c, 58.02; H, 6.04.

**Example 6: Preparation of (-)-(2S,4S) and (2S,4R)-4-Acetoxy-2-(O-benzoyloxymethyl)-dioxolane (8)**

A solution of  $NaIO_4$  (10.18 g, 0.048 mol) in  
30 water (120 mL) was added to a solution of (6) (3.04 g, 0.011 mol) in  $CCl_4:CH_3CN$  (1:1, 160 mL), followed by  $RuO_2$  hydrate (0.02 g). After the reaction mixture was stirred for 5 hours, the solid was removed by filtration over Celite and the filtrate  
35 was evaporated to 1/3 volume. The residue was dissolved in  $CH_2Cl_2$  (100 mL) and the water layer was extracted with  $CH_2Cl_2$  (100 mL X 2). The combined organic layer was washed with brine (50 mL), dried

(MgSO<sub>4</sub>), filtered, evaporated to dryness and dried in vacuo for 16 hours to give crude (7) (2.6 g, 91%).

To a solution of crude (7) (2.6, 0.01 mol) in dry THF (60 mL) were added Pb(OAc)<sub>4</sub> (5.48 g, 0.0124 mol) and pyridine (0.83 mL, 0.0103 mol) under N<sub>2</sub> atmosphere. The mixture was stirred for 45 minutes under N<sub>2</sub> and the solid was removed by filtration. The solid was washed with ethyl acetate (60 mL) and the combined organic layer was evaporated to dryness. The residue was purified by silica gel column chromatography (Hexane-EtOAc, 2:1) to yield (8) [R<sub>f</sub> = 0.73 and 0.79 (Hexane-EtOAc, 2:1), 1.9 g, 69.34%] as a colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 1.998, 2.11 (2X s, 3H, -OAc), 3.93-4.33 (m, 2H, H-5), 4.43, 4.48 (2 X d, J= 3.73, 3.74 Hz, 2H, CH<sub>2</sub>OBz), 5.46, 5.55 (2 X t, J= 4.18, 3.63 Hz, 1H, H-2), 6.42 (m, 1H, H-4), 7.33-7.59, 8.00-8.15 (m, 3H, 2H, -OBz). [α]<sub>D</sub><sup>25</sup> -12.53 (c, 1.11, CHCl<sub>3</sub>). Anal. Calcd for C<sub>13</sub>H<sub>14</sub>O<sub>6</sub>; C, 58.64; H, 5.30. Found C, 58.78; H, 5.34.

**Example 7:** Preparation of (-)-(2S,4S)-1-[2-(benzoyl)-1,3-dioxolan-4-yl]cytosine (9) and (+)-(2S,4R)-1-[2-(benzyloxy)-1,3-dioxolan-4-yl]cytosine (10)

A mixture of N<sup>4</sup>-acetylcytosine (1.24 g, 7.52 mmol) in dry dichloroethane (20 mL), hexamethyldisilazane (15 mL), and ammonium sulfate (cat. amount) was refluxed for 4 hours under a nitrogen atmosphere. The resulting clear solution was cooled to room temperature. To this silylated acetylcytosine was added a solution of (8) (1.0 g, 3.76 mmol) in dry dichloroethane (10 mL) and TMSOTf (1.46 mL 7.55 mmol). The mixture was stirred for 6 hours. Saturated NaHCO<sub>3</sub> (10 mL) was added and the mixture was stirred for another 15 minutes and filtered through a Celite pad. The filtrate was evaporated and the solid was dissolved in EtOAc and washed with water and brine, dried, filtered and

evaporated to give the crude product. This crude product was purified on a silica column (5% CH<sub>3</sub>OH/CHCl<sub>3</sub>) to yield a pure  $\alpha,\beta$  mixture of (9) and (10) (0.40 g, 30%) and the  $\alpha,\beta$  mixture of (13) and (14) (0.48 g, 40%). The mixture of (14) was reacetylated for separation, the combined  $\alpha,\beta$  mixture was separated by a long silica column (3% CH<sub>3</sub>OH/CHCl<sub>3</sub>) to yield (9) (0.414 g, 30.7%) and (10) (0.481 g, 35.6%) as foams. These foams were triturated with CH<sub>3</sub>OH to obtain white solids. 9: UV (CH<sub>3</sub>OH)  $\lambda$  max 298 nm; Anal. (C<sub>17</sub>H<sub>17</sub>N<sub>3</sub>O<sub>8</sub>) C, H, N. 10: UV (CH<sub>3</sub>OH)  $\lambda$  max 298 nm.

**Example 8: Preparation of (-)-(2S,4S)-1-(2-Hydroxymethyl-1,3-dioxolan-4-yl)cytosine (11)**

A solution of (9) (0.29 g, 0.827) in CH<sub>3</sub>OH/NH<sub>3</sub> (50 mL, saturated at 0°C) was stirred at room temperature for 10 hours. The solvent was evaporated and the crude (11) was purified on preparative silica plates (20% CH<sub>3</sub>OH/CHCl<sub>3</sub>) to give an oil. This was crystallized from CH<sub>2</sub>Cl<sub>2</sub>/hexane to give (11) (0.136 g, 77.7%) as a white solid. UV  $\lambda$  max 278.0 nm ( $\epsilon$  11967) (pH 2), 270.0 nm ( $\epsilon$  774) (pH 7), 269.0 nm ( $\epsilon$  8379) (pH 11); Anal. (C<sub>8</sub>H<sub>11</sub>N<sub>3</sub>O<sub>4</sub>)C,H,N.

**II. Pharmaceutical Compositions**

Humans, equines, canines, bovines and other animals, and in particular, mammals, suffering from tumors, and in particular, cancer, can be treated by administering to the patient an effective amount of (-)-OddC or its derivative or a pharmaceutically acceptable salt thereof optionally in a pharmaceutically acceptable carrier or diluent, either alone, or in combination with other known anticancer or pharmaceutical agents. This treatment can also be administered in conjunction with other conventional cancer therapies, such as radiation treatment or surgery.

These compounds can be administered by any appropriate route, for example, orally, parenterally, intravenously, intradermally, subcutaneously, or topically, in liquid, cream, gel, or solid form, or by aerosol form.

The active compound is included in the pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to a patient a therapeutically effective amount for the desired indication, without causing serious toxic effects in the patient treated. A preferred dose of the compound for all of the herein-mentioned conditions is in the range from about 10 ng/kg to 300 mg/kg, preferably 0.1 to 100 mg/kg per day, more generally 0.5 to about 25 mg per kilogram body weight of the recipient per day. A typical topical dosage will range from 0.01 - 3% wt/wt in a suitable carrier.

The compound is conveniently administered in any suitable unit dosage form, including but not limited to one containing 1 to 3000 mg, preferably 5 to 500 mg of active ingredient per unit dosage form. A oral dosage of 25-250 mg is usually convenient.

The active ingredient is preferably administered to achieve peak plasma concentrations of the active compound of about 0.00001 - 30 mM, preferably about 0.1 - 30  $\mu$ M. This may be achieved, for example, by the intravenous injection of a solution or formulation of the active ingredient, optionally in saline, or an aqueous medium or administered as a bolus of the active ingredient.

The concentration of active compound in the drug composition will depend on absorption, distribution, inactivation, and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further

understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition. The active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.

Oral compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound or its prodrug derivative can be incorporated with excipients and used in the form of tablets, troches, or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.

The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a dispersing agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, dosage unit forms can contain various other materials which modify the physical form of the dosage unit,

for example, coatings of sugar, shellac, or enteric agents.

5       The active compound or pharmaceutically acceptable salt thereof can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like. A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.

10       The active compound or pharmaceutically acceptable salts thereof can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as other anticancer  
15       agents, antibiotics, antifungals, antiinflammatories, or antiviral compounds.

      Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile  
20       diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as  
25       ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parental preparation can  
30       be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

      If administered intravenously, preferred carriers are physiological saline or phosphate buffered saline (PBS).

35       In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.

Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.

Liposomal suspensions may also be pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811 (which is incorporated herein by reference in its entirety). For example, liposome formulations may be prepared by dissolving appropriate lipid(s) (such as stearyl phosphatidyl ethanolamine, stearyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. An aqueous solution of the active compound are then introduced into the container. The container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.

### III. Biological Activity

A wide variety of biological assays have been used and are accepted by those skilled in the art to assess anti-cancer activity of compounds. Any of these methods can be used to evaluate the activity of the compounds disclosed herein.

One common method of assessing activity is through the use of the National Cancer Institute's ("NCI") test panels of cancer cell lines. These tests evaluate the in vitro anti-cancer activity of particular compounds, and provide predictive data with respect to the use of tested compounds in vivo. Other assays include in vivo evaluations of the compound's effect on human or mouse tumor cells



implanted into or grafted onto nude mice. (-)-OddC was tested for anticancer activity in vivo against the P388 leukemia cell line and the C38 colon cancer cell line. Examples 9 and 10 provide the experimental details and results of these tests.

**Example 9            In Vivo Treatment Of Leukemia P388 Cells With (-)-O-ddC**

10<sup>6</sup> Leukemia P388 cells were implanted ip to BDF1 mice obtained from Southern Research Institute, Alabama. (-)-OddC was administered ip twice daily for five days starting one day after tumor cell implantation. Using this protocol, 75 mg/kg/dose was shown to be toxic to the mice.

Figure 3 and Table 1 show the results of these studies. In Figure 3, (●) represents the data for the control (untreated animals), (--Δ--) represents the survival rate of those administered (-)-OddC at 25 mg/kgbid twice a day, and (○) represents the survival rate of mice administered (-)-OddC once a day at 50 mg/kgbid. Of the six mice treated with 25 mg/kg/dose of (-)-OddC, there is one long term survivor, and the life span of the remaining five mice was increased by 103%.

Table 1

Group	Dosage <sup>a</sup> (mg/kg)	Route	Mean Survival Time (days)	ILS <sup>b</sup> (%)	Death Time(day)	Cures/ Total
5	Control	--	13.3	--	11,12,13 13,13,18	0/6
	-OddC 25x2x5	ip	27	103	18,20,22, 25,33,45	1/6

10 Inoculum: 10<sup>6</sup> P388 cells were inoculated into each mouse ip on day 0  
a: Treatment was given twice a day on days 1 to 5  
b: Increased Life Span percent above control  
c: Survivors equal or greater than 45 day life span

**Example 10      In Vivo Treatment Of Colon 38 Tumor Cells With (-)-OddC**

Colon 38 tumor cells were implanted sc to BDF1 mice. (-)-OddC was administered to the mice twice  
 5 daily for five days, at a dosage of 25 mg/kg/dose. The colon tumor cell growth was retarded as shown in Figure 2. In Figure 2, (●) represents the data from the control animals, and (▲) represents the data from the mice treated with (-)-OddC.

10 **Example 11      In Vitro Testing of (-)-OddC**

(-)-OddC was evaluated in the NCI's cancer screening program. The test measures the inhibition of various cancer cell lines at various concentrations of (-)-OddC. The cell lines which  
 15 were tested are set forth in Table 2.

Table 2 also provides the concentration at which GI50 and TGI were observed in the tested cell lines. GI50, TGI and LC50 are values representing the concentrations at which the PG (percent of growth inhibition), defined below, is +50, 0, and -50, respectively. These values were determined by  
 20 interpolation from dose response curves established for each cell line, plotted as a function of PG v.  $\log_{10}$  concentration of (-)-OddC.

25 PG is the measured effect of (-)-OddC on a cell line and was calculated according to one of the following two expressions:

If  $(\text{Mean OD}_{\text{test}} - \text{Mean OD}_{\text{zero}}) \geq 0$ . then

30 
$$\text{PG} = 100 \times (\text{Mean OD}_{\text{test}} - \text{Mean OD}_{\text{zero}}) / (\text{Mean OD}_{\text{ctrl}} - \text{Mean OD}_{\text{zero}})$$

If  $(\text{Mean OD}_{\text{test}} - \text{Mean OD}_{\text{zero}}) < 0$ . then

$$\text{PG} = 100 \times (\text{Mean OD}_{\text{test}} - \text{Mean OD}_{\text{zero}}) / (\text{Mean OD}_{\text{zero}})$$

Where:

35  $\text{Mean OD}_{\text{zero}} =$  The average of optical density measurements of SRB-derived color just before exposure of cells to the test compound.

Mean OD<sub>test</sub> = The average of optical density measurements of SRB-derived color after 48 hours exposure of cells to the test compound.

5 Mean OD<sub>ctrl</sub> = The average of optical density measurements of SRB-derived color after 48 hours with no exposure of cells to the test compound.

10 In Table 2, the first two columns describe the subpanel (e.g., leukemia) and cell line (e.g., CCRF-CEM) which were treated with (-)-OddC. Column 3 indicates the log<sub>10</sub> at which GI50 occurred and column 4 indicates the log<sub>10</sub> at which TGI occurred. If these response parameters could not be obtained  
15 by interpolation, the value given for each response parameter is the highest concentration tested and is preceded by a ">" sign. For example, if all the PG at all concentrations of (-)-OddC given to a particular cell line exceeds +50, then this  
20 parameter can not be obtained by interpolation.

Table 2

Panel	Cell Line	Log <sub>10</sub> GI50	Log <sub>10</sub> TGI
Leukemia	CCRF-CEM	-6.64	> -4.00
	RL-60(TB)	-6.28	> -4.00
	K-562	-4.59	> -4.00
	BSOLT-4	-6.66	-4.39
	RPMI-2.26	-4.03	> -4.00
	SR	-5.95	> -4.00
Non-Small Cell Lung Cancer	A549/ATCC	-6.01	> -4.00
	BKVX	> -4.00	> -4.00
	HOP-62	-6.23	-4.71
	NCI-H23	-4.92	> -4.00
	NCI-H322M	> -4.00	> -4.00
	NCI-H460	-4.32	> -4.00
	NCI-H522	-6.06	> -4.00
Colon Cancer	COLO205	-4.03	> -4.00
	HCT-116	-5.23	> -4.00
	HCT-15	-5.39	> -4.00
	HT29	> -4.00	> -4.00
	K2112	> -4.00	> -4.00
CNS Cancer	SP-268	-5.18	> -4.00
	SP-295	-6.24	> -4.00
	SNB-19	-5.71	> -4.00
	U251	-4.91	> -4.00
Melanoma	LOX D6VI	-6.39	> -4.00
	MALME-3M	-4.51	> -4.00
	M14	-6.27	-5.07
	SK-MEL-28	-4.31	> -4.00
	SK-MEL-5	-4.91	> -4.00
PANEL	CELL LINE	LOG <sub>10</sub> GI50	LOG <sub>10</sub> TGI
	UACC-257	> -4.00	> -4.00
	UACC-62	-5.53	> -4.00

Ovarian Cancer	OROV1	-4.03	> -4.00
	OVCAR-3	-4.44	> -4.00
	OVCAR-4	> -4.00	> -4.00
	OVCAR-5	-4.41	> -4.00
	OVCAR-8	-5.82	> -4.00
	SK-OV-3	-5.35	> -4.00
Renal Cancer	785-4	-5.36	> -4.00
	ACHN	-6.46	> -4.00
	CAKI-1	-6.65	-4.87
	RXF-393	-6.17	> -4.00
	SN12C	-6.27	> -4.00
	TK-30	> -4.00	> -4.00
	UO-31	-5.60	> -4.00
Prostate Cancer	PC-3	-6.29	> -4.00
	DU-145	-6.97	> -4.00
Breast Cancer	MCF7	-5.95	> -4.00
	MCF7/ADR-RES	-4.97	> -4.00
	MDA-MB-231/ATCC	> -4.00	> -4.00
	HS578T	> -4.00	> -4.00
	MDA-MB-435	-4.62	> -4.00
	MDA-N	-4.33	> -4.00
	BT-549	-4.59	> -4.00
	T-47D	> -4.00	> -4.00

Figure 4 is a graph that displays the relative selectivity of (-)-OddC for a particular cell line. Bars extending to the right represent sensitivity of the cell line to (-)-OddC in excess of the average sensitivity of all tested cell lines. Since the bar scale is logarithmic, a bar 2 units to the right implies the compound exhibited a GI50 for the cell line at a concentration one-hundredth the mean concentration required over all cell lines, and thus the cell line is unusually sensitive to (-)-OddC. Bars extending to the left correspondingly imply sensitivity less than the mean. These cell lines can be easily determined from Table 2, as the log<sub>10</sub> concentration will be preceded by a ">".

It can be seen from Figure 4 that at least one cell line of each type of cancer cell tested exhibited sensitivity to (-)-OddC. Certain prostate cancer cell lines, leukemia cell lines, and colon cell lines show extreme sensitivity to (-)-OddC.

#### Example 12 Comparison of (-)-OddC and AraC

As discussed in the Background of the Invention, cytosine arabinoside (also referred to as Cytarabin, araC, and Cytosar) is a nucleoside analog of deoxycytidine used in the treatment of acute myeloid leukemia. It is also active against acute lymphocytic leukemia, and to a lesser extent, is useful in chronic myelocytic leukemia and non-Hodgkin's lymphoma. The primary action of araC is inhibition of nuclear DNA synthesis. It was of interest to compare the toxicity to tumor cells of (-)-OddC and AraC.

Cells in logarithmic growth were plated at a density of 5000 cells/mL/well in 24-well plates. Drugs were added to the cells at different dosages and cultures were maintained for a period of three generations. At the end of this time, methylene

blue assays were performed and/or cell numbers were directly counted. Methylene blue is a dye which binds in a stoichiometric manner to proteins of viable cells and can be used to indirectly  
5 quantitate cell number (Finlay, 1984).  $IC_{50}$  values were determined by interpolation of the plotted data. Each value shown is the mean  $\pm$  standard deviation of five experiments with each data point done in duplicate.

10 In all of the tumor cell lines tested, (-)-OddC was more cytotoxic than AraC. (-)-OddC was significantly more effective than AraC in the KB nasopharyngeal carcinoma cell line and in the two prostate carcinoma lines DU-145 and PC-3.  
15 HepG2 cells originate from hepatocellular carcinoma and the 2.2.15 line is derived from HepG2 cells which were transfected with a copy of the hepatitis B virus genome. CEM cells are derived from acute lymphoblastic leukemia. (-)-OddU, the compound  
20 which would be formed by the deamination of (-)-OddC was not toxic in any of the cell lines tested. Enzymatic studies indicate that, unlike AraC whose clinical efficacy is greatly diminished by its susceptibility to deamination, (-)-OddC is  
25 not a substrate for deaminase.

It has been determined that (-)-OddC can be phosphorylated to mono-, di- and tri-phosphate nucleotide in vivo. It appears that (-)-OddC exhibits its cellular toxicity in a phosphorylated  
30 form because cells that are incapable of phosphorylating the compound are much less sensitive to the compound. The first enzyme responsible for its phosphorylation is human deoxycytidine kinase. *In vitro* enzymatic studies  
35 indicate that (-)-OddC can be phosphorylated by this enzyme.

Unlike araC, (-)-OddC is not deaminated by cytidine deaminase. The presence of cytidine deaminase in solid tumor tissues can be a key



contributing factor responsible for the lack of activity of araC in solid tumors. This could partly explain why (-)-OddC is active against HepG2 cells in nude mice, whereas araC is inactive. It  
5 also explains why (-)-OddC has different spectrums of anti-tumor activity from that of araC. Furthermore, the presence of cytidine deaminase in the gastrointestinal tract may play an important role in why araC cannot be taken orally.

**BIOCHEMICAL STUDIES OF (-)-Oddc**  
*In vitro* cytotoxicity of AraC, (-)-Oddc and (-)-Oddu

5	Cell Line	AraC	ID <sub>50</sub> (μM)	
			(-)-Oddc	(-)-Oddu
10	KB	0.152 ± .010	0.048 ± .021	>30
	DU-145	0.170 ± .035	0.024 ± .020	>30
	PC-3	0.200 ± .078	0.056 ± .039	>30
	HepG2	0.125 ± .013	0.110 ± .050	>30
	2.2.15	0.145 ± .007	0.110 ± .011	>30
	CEM	0.030 ± .010	0.025 ± .030	>30

**Example 12 In Vivo Studies**

Three to six-week-old NCr nude mice (Taconic Immunodeficient Mice and Rats) were inoculated s.c. in each flank with  $2 \times 10^6$  HepG2 or DU-145 cells and tumors were allowed to grow. Treatment was started when the tumors were 100-250mg as determined by caliper measurement and calculated according to the formula:

$$\text{Tumor Weight (mg)} = \text{length (mm)} \times \text{width (mm)}^2 + 2$$

Drugs were given at the indicated doses on days 0 through 4 and tumor sizes were measured every several days. The tumor growth curves were generated as described in Bell, et al., *Cancer (phila.)* 36:2437-2440 (1975), and are illustrated in Figures 5(a) and 5(b).

Toxicity was evaluated by changes in body weight.

Although the *in vitro* toxicity of AraC was similar to that of (L)-OddC, AraC was ineffective in this animal model. Enzymatic analysis of tumor extract indicated that this was not due to increased dCD activity or decreased dCK activity but may have been the result of extensive AraC metabolism in the liver which had high dCD levels. Unlike AraC, (L)-OddC was effective in both HepG2 and DU-145 xenografts. The net cell kill (log 10) calculated for HepG2 tumors were 0.67 and 0.87 for i.p. and oral treatment respectively. The DU-145 tumors become smaller in size with half of them regressing completely by day 15. The tumors did begin to reappear about 25 days after the last treatment but growth stopped again after day 47. On day 60 the animals were sacrificed and tumors were removed. The tumors had a necrotic morphology with very few of the cells being able to exclude trypan blue. In addition, no enzyme activities

could be detected in this tissue. The doses of AraC and (L)-OddC given were equally toxic as indicated by weight loss of the animals, and preliminary toxicity experiments suggest that  
5 25mg/kg twice a day may be the maximum tolerated dosage for five continuous days of treatment. A protocol in which drug is administered on an intermittent basis may be preferred.

The *in vitro* and *in vivo* data shown here  
10 demonstrate that (L)-OddC has significant anti-cancer activity and may in many ways be superior to deoxycytidine analogs currently available. Not only is it the first L-nucleoside analog ever shown to have anti-cancer activity, but it is also the  
15 first true chain-terminator capable of inhibiting tumor growth. Although its unnatural stereochemistry does not prevent (L)-OddC from being activated by metabolic enzymes or from being incorporated into DNA, it may be a factor which  
20 protects this compound from degradation by dCD. (L)-OddC is also unique in that it is active in solid tumors which are usually unresponsive to nucleoside analog therapy. The drug 2',2'-difluorodeoxycytidine (gemcitabine), which is  
25 currently undergoing clinical evaluation for the treatment of solid tumors, is still susceptible to inactivation by dCD(16). Because the elevation of dCD levels is a mechanism by which cells become resistant to dCyd analogs such as AraC(17), (L)-  
30 OddC can be useful in the treatment of patients who have become unresponsive to these drugs.

#### IV. Use of (-)-OddC in Oligonucleotides and in Antisense Technology

Antisense technology refers in general to the modulation of gene expression through a process wherein a synthetic oligonucleotide is hybridized to a complementary nucleic acid sequence to inhibit transcription or replication (if the target sequence is DNA), inhibit translation (if the target sequence is RNA) or to inhibit processing (if the target sequence is pre-RNA). A wide variety of cellular activities can be modulated using this technique. A simple example is the inhibition of protein biosynthesis by an antisense oligonucleotide bound to mRNA. In another embodiment, a synthetic oligonucleotide is hybridized to a specific gene sequence in double stranded DNA, forming a triple stranded complex (triplex) that inhibits the expression of that gene sequence. Antisense oligonucleotides can be also used to activate gene expression indirectly by suppressing the biosynthesis of a natural repressor or directly by reducing termination of transcription. Antisense Oligonucleotide Therapy (AOT) can be used to inhibit the expression of pathogenic genes, including those which are implicated in the uncontrolled growth of benign or malignant tumor cells or which are involved in the replication of viruses, including HIV and HBV.

The stability of the oligonucleotides against nucleases is an important factor for in vivo applications. It is known that 3'-exonuclease activity is responsible for most of the unmodified antisense oligonucleotide degradation in serum. Vlassov, V.V., Yakubov, L.A., in Prospects for Antisense Nucleic Acid Therapy of Cancers and AIDS, 1991, 243-266, Wiley-Liss, Inc., New York; Nucleic Acids Res., 1993, 21, 145.

The replacement of the nucleotide at the 3'-end of the oligonucleotide with (-)-OddC or its derivative can stabilize the oligonucleotide

against 3'-exonuclease degradation. Alternatively  
or in addition, an internal nucleotide can be  
replaced by (-)-OddC or its derivative to resist  
the degradation of the oligonucleotide by  
5 endonucleases.

Given the disclosure herein, one of ordinary  
skill in the art will be able to use (-)-OddC or  
its derivative to stabilize a wide range of  
oligonucleotides against degradation by both  
10 exonucleases and endonucleases, including  
nucleosides used in antisense oligonucleotide  
therapy. All of these embodiments are considered  
to fall within the scope of this invention.  
Example 13 provides one, non-limiting, example of  
15 the use of (-)-OddC to resist the activity of a 3'-  
exonuclease.

**Example 13      Resistance to 3'-Exonuclease  
Activity By (-)-OddC**

The human cytosolic exonuclease activity from  
20 human H9 (T-type lymphocytic leukemic cells) was  
determined by sequencing gel assay. Briefly, the  
3'-terminated substrate was prepared from a 20 or  
23 base-long DNA primer with the following  
sequence:

25            3'-CAATTTTGAATTCCTTAACTGCC-5'

24

1

The primers were labelled at the 5'-end with [T-  
<sup>32</sup>P]ATP, annealed to complementary RNA templates and  
terminated at the 3' end with dTTP (20 mer) dCTP  
30 (23 mer) or (-)-OddCTP (23 mer) in a standing start  
reaction catalyzed by HIV-1 RT. Under these  
conditions, the 20mer was terminated with dTMP (A)  
the 23mer was terminated with dCMP (B) or  
(-)-O-ddCMP(C). These single stranded DNA  
35 substrates were used to assay their susceptibility  
to the cytoplasmic exonuclease. The assays were  
done in 10 µl reactions containing 50 mM Tris-HCl

pH 8.0, 1mM MgCl<sub>2</sub>, 1mM dithiothreitol, 0.1 mg/ml bovine serum albumin, 0.18  $\mu$ Ci/ml 3'-terminated substrate and 2  $\mu$ l of the exonuclease (0.03 units). The reactions were incubated at 37°C for the

5 indicated times and terminated by adding 4  $\mu$ l 98% formamide, 10 mM EDTA and 0.025% bromophenol blue. The samples were denatured at 100°C for 5 minutes followed by rapid cooling on ice. The unreacted material as well as the reaction products were


10 separated on 15% polyacrylamide/urea sequencing gels and visualized by autoradiography. The oligonucleotide with (-)-OddC at the 3'-end was at least five times more resistant to 3'-exonuclease than the other oligonucleotides.

15 Modifications and variations of the present invention in the treatment of cancer will be obvious to those skilled in the art from the foregoing detailed description of the invention. Such modifications and variations are intended to

20 come within the scope of the appended claims.

We claim:

1. The  $\beta$ -L-enantiomer of a compound of formula:



wherein R<sup>1</sup> and R<sup>2</sup> are selected from the group consisting of hydrogen, acyl and C<sub>1</sub> to C<sub>18</sub> alkyl, which is at least 95% free of the corresponding  $\beta$ -D-enantiomer.

2. The compound of claim 1, wherein R<sup>1</sup> and R<sup>2</sup> are hydrogen.

3. The compound of claim 1, wherein the alkyl group is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, t-butyl, and isopentyl.

4. The compound of claim 1, wherein the acyl group is -C(O)R, wherein R is a C<sub>1</sub> to C<sub>3</sub> alkyl group, phenyl, or benzyl.

5. A pharmaceutical composition comprising an effective amount to treat a tumor in a host animal of the compound of claim 1 or 2, or its pharmaceutically acceptable salt, in a pharmaceutically acceptable carrier.

6. The composition of claim 5, wherein the carrier is suitable for oral delivery.

7. The composition of claim 5, wherein the carrier is suitable for intravenous delivery.

8. The composition of claim 5, wherein the carrier is suitable for topical or transdermal delivery.



9. A method for treating a tumor in a host animal comprising administering to a host animal an effective amount of the compound of claim 1 or 2.

10. The method of claim 9, wherein the host animal is a human.

11. The method of claim 9, wherein the tumor is cancerous and the cancer is prostate cancer.

12. The method of claim 9, wherein the tumor is cancerous and the cancer is leukemia.

13. The method of claim 9, wherein the tumor is cancerous and the cancer is colon cancer.

14. The method of claim 9, wherein the tumor is cancerous and the cancer is bladder.

15. The method of claim 9, wherein the tumor is cancerous and the cancer is hepatocellular.

16. The method of claim 9, wherein the tumor is cancerous and the cancer is breast.

17. The method of claim 9, wherein the tumor is cancerous and the cancer is lung cancer.

18. The method of claim 9, wherein the tumor is cancerous and the cancer is nasopharyngeal.


19. The method of claim 9, wherein the tumor is cancerous and the cancer is pancreatic.

20. The method of claim 9, wherein the tumor is cancerous and the cancer is ovarian.

21. The method of claim 9, wherein the tumor is cancerous and the cancer is lymphoma.

22. The method of claim 9, wherein the tumor is cancerous and the cancer is hepatocellular.

23. A method for the treatment of cancer in a host that includes administration of an effective amount of a compound of the formula:



wherein R is selected from the group consisting of H, F, Cl,  $-CH_3$ ,  $-C(H)=CH_2$ ,  $-C=CH$ , or  $-C\equiv N$ , Br,  $-NO_2$ , and R<sup>1</sup> and R<sup>2</sup> is selected from the group consisting of hydrogen, alkyl, acyl, monophosphate, diphosphate, and triphosphate, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.

24. The method of claim 23, wherein R is fluorine, and R<sup>1</sup> and R<sup>2</sup> are hydrogen.

25. The method of claim 23 or 24, wherein the host animal is a human.

26. The method of claim 23 or 24, wherein the tumor is cancerous and the cancer is prostate cancer.

27. The method of claim 23 or 24, wherein the tumor is cancerous and the cancer is leukemia.

28. The method of claim 23 or 24, wherein the tumor is cancerous and the cancer is colon cancer.

29. The method of claim 23 or 24, wherein the tumor is cancerous and the cancer is bladder.

30. The method of claim 23 or 24, wherein the tumor is cancerous and the cancer is hepatocellular.

31. The method of claim 23 or 24, wherein the tumor is cancerous and the cancer is breast.

32. The method of claim 23 or 24, wherein the tumor is cancerous and the cancer is lung cancer.

33. The method of claim 23 or 24, wherein the tumor is cancerous and the cancer is nasopharyngeal.

34. The method of claim 23 or 24, wherein the tumor is cancerous and the cancer is pancreatic.

35. The method of claim 23 or 24, wherein the tumor is cancerous and the cancer is ovarian.

36. The method of claim 23 or 24, wherein the tumor is cancerous and the cancer is lymphoma.

37. The method of claim 23 or 24, wherein the tumor is cancerous and the cancer is hepatocellular.

38. A pharmaceutical composition comprising an effective amount to treat a tumor in a host animal of the compound of claim 23 or 24, or its pharmaceutically acceptable salt, in a pharmaceutically acceptable carrier.


39. The method of claims 9, 23 or 24, wherein the carrier is suitable for oral delivery.

40. The method of claims 9, 23, or 24, wherein the carrier comprises a capsule.

41. The method of claims 9, 23, or 24, wherein the carrier is in the form of a tablet.


42. The method of claims 9, 23, or 24, wherein the administration is parenteral.

43. A process for the preparation of (-)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine comprising reacting optionally protected cytosine with a 1,3-dioxolane of the formula:



wherein  $R_{1a}$  is hydrogen or a hydroxyl protecting group, including an acyl group, and L is a leaving group, and optionally removing any hydroxyl protecting group.

44. A process for the preparation of 2-hydroxymethyl-5-(cytosin-1-yl)-1,3-dioxolane comprising reacting a compound of the formula:



wherein  $R_{12}$  is a hydroxyl protecting group,

with an agent that converts the oxo group in the 4-position of the uracil ring to an amino group, and then removing the protecting groups.

45. A process for the preparation of (2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine which comprises:

reacting a protected 1,3-dioxolane of the formula:



with a protected cytosine base that is optionally substituted in the 5-position, using a Lewis acid that does not racemize the product.

46. (-)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine and derivatives and salts thereof, or the (+)-enantiomer or racemic mixture thereof, and pharmaceutically acceptable derivatives and salts thereof for use in medical therapy, for example for the treatment or prophylaxis of a tumor, including a cancerous tumor.


47. Use of (-)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine and pharmaceutically acceptable derivatives and salts thereof, or the (+)-enantiomer or racemic mixture thereof, and pharmaceutically acceptable derivatives and salts thereof in the manufacture of a medicament for treatment of a tumor, including a cancerous tumor.

48. (-)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine and derivatives and salts thereof, or the (+)-enantiomer or racemic mixture

thereof, and pharmaceutically acceptable derivatives and salts thereof for use in medical therapy, for example for the treatment or prophylaxis of an abnormal or undesired proliferation of cells.

49. The use of (-)-(2S,4S)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)cytosine and pharmaceutically acceptable derivatives and salts thereof, or the (+)-enantiomer or racemic mixture thereof, and pharmaceutically acceptable derivatives and salts thereof in the manufacture of a medicament for the treatment of abnormal or undesired proliferation of cells.

FIGURE 1



Growth Inhibition % Control Growth

FIGURE 2




FIGURE 3






FIGURE 4




FIGURE 5A





FIGURE 5B



% Original Tumor Weight

5 / 5

SUBSTITUTE SHEET (RULE 26)

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/11464

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 31/505; C07D 405/04

US CL :544/310, 313, 314, 317; 514/274

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 544/310, 313, 314, 317; 514/274

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
CAS ONLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 4,000,137 (DVONCH ET AL) 28 December 1976, see entire document.	1
A	US, A, 4,336,381 (NAGATA ET AL) 22 June 1982, see entire document.	1
Y	US, A, 5,041,449 (BELLEAU ET AL) 20 August 1991, see formula L, Flowsheet I and II, and claims 1-5.	1-8,43-49
Y	EP, A, 337,713 (IAF BIOCHEM INTERNATIONAL INC.) 18 October 1989, see formula L and Flowsheet I and II.	1-8,43-49
Y	US, A, 5,179,104 (CHU ET AL) 12 January 1993, see Figure 2.	43-49



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	
*A* document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*E* earlier document published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*O* document referring to an oral disclosure, use, exhibition or other means	*Z* document member of the same patent family
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

27 NOVEMBER 1995

Date of mailing of the international search report

11 JAN 1996

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Authorized officer

CECILIA TSANG

Facsimile No. (703) 305-3230

Telephone No. (703) 308-1235

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**